[Form 4] Cassava Sciences, Inc. Insider Trading Activity

Filing Impact

(Low)

Filing Sentiment

(Neutral)

Form Type

4

07/16/2025 - 04:04 PM

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Cassava Sciences

NASDAQ:SAVA

SAVA Rankings

#4728 Ranked by Market Cap

N/A Ranked by Dividends

SAVA Latest News

Aug 25, 2025

Cassava Sciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 14, 2025

Cassava Reports Q2 2025 Financials Results and Provides Business Update

Aug 7, 2025

Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer

Aug 4, 2025

Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy

Jun 30, 2025

Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting

SAVA Latest SEC Filings

Aug 14, 2025

[10-Q] Cassava Sciences, Inc. Quarterly Earnings Report

Aug 14, 2025

[8-K] Cassava Sciences, Inc. Reports Material Event

Aug 4, 2025

[8-K] Cassava Sciences, Inc. Reports Material Event

Jul 29, 2025

[SCHEDULE 13G/A] Cassava Sciences, Inc. SEC Filing

Jun 30, 2025

[8-K] Cassava Sciences, Inc. Reports Material Event

SAVA Stock Data

Market Cap 103.86M

Float 42.13M

Insiders Ownership 12.79%

Institutions Ownership 25.2%

Short Percent 13.09%

Industry Biotechnology

Sector Pharmaceutical Preparations

Website Link

Country United States

City AUSTIN